| CAS | 514200-66-9 |
| Sequence | Ac-Leu-Arg-Val-Arg-Leu-Ala-Ser-His-Leu-Arg-Lys-Leu-Arg-Lys-Arg-Leu-Leu-NH2 |
| Sequence Single | Ac-LRVRLASHLRKLRKRLL-NH2 |
| Molecular Formula | C97H181N37O19 |
| Molecular Weight | 2169.73 |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Description | COG 133 is an apolipoprotein (ApoE) peptide fragment that functions via the low-density lipoprotein receptor-related protein (LRP). COG 133 substantially reduces the symptoms of experimental autoimmune encephalomyelitis, a model of human multiple sclerosis, and suppresses inflammation, demyelination and infiltration of cells into the spinal cord. COG 133 also acts as a non-competitive antagonist at α7 nicotinic acetylcholine receptors (IC50 = 445 nM). |
| References | 1. Apolipoprotein E-derived peptides block α7 neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. Gay et al (2006). J.Pharmacol.Exp.Ther. 316 835 PMID: 16249370 2. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. Li et al (2006). J.Pharmacol.Exp.Ther. 318 956 PMID: 16740622 3. N-MthD.-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. Sheng et al (2008). Neuropharmacology 55 204 PMID: 18602124 4. Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. Orleâncio Gomes R Azevedo, et al. BMC Gastroenterol. 2012 Jul 13;12:35. |